Background
Methods
Setting
Study Design and Definitions
Statistical Methods
Results
Risk Factorb
| Death during admission | No death during admission | OR (95% CI) | P value |
---|---|---|---|---|
N | 36 | 253 | ||
Demographics | ||||
Male | 22 (61) | 176 (70) | 0.31 | |
Race/Ethnicity | 0.46 | |||
Black | 22 (61) | 145 (50) | ||
Hispanic | 9 (25) | 44 (15) | ||
Other race | 2 (6) | 23 (8) | ||
White | 3 (8) | 41 (14) | ||
Age | 51.6 (15.8) | 47.6 (15.3) | 0.15 | |
Microbiological Factors | ||||
Epidemiologic risk | 0.76 | |||
Community associated | 11 (31) | 69 (27) | ||
Healthcare associated | 8 (22) | 71 (28) | ||
Hospital onset | 17 (47) | 113 (45) | ||
MRSA | 17 (47) | 103 (41) | 0.46 | |
Urine culture positive | 14 (39) | 43 (17) | 3.11 (1.47 - 6.55) | 0.002 |
Clinical Factors | ||||
HIV | 6 (17) | 28 (11) | 0.32 | |
Bladder catheter | 19 (53) | 86 (34) | 2.17 (1.07 - 4.39) | 0.03 |
Charlson score | 2.84 | 2.04 | 0.22 | |
Hemodialysis | 1 (3) | 26 (11) | 0.24 (0.03 - 1.90) | 0.15 |
Immunosuppressed | 8 (22) | 45 (18) | 0.52 | |
Urological surgery | 0 (0) | 13 (5) | 0.16 | |
DM | 13 (36) | 70 (28) | 0.30 | |
IVDA | 4 (11) | 42 (17) | 0.40 | |
Prosthetic device | 3 (8) | 63 (25) | 0.27 (0.08-0.92) | 0.03 |
Alcoholism | 7 (19) | 40 (16) | 0.58 | |
ID consult or managementc
| 18 (50) | 128 (60) | 0.25 | |
Line/phlebitis | 2 (6) | 56 (22) | 0.21 (0.05-0.89) | 0.02 |
Skin soft tissue infection | 7 (19) | 50 (20) | 0.96 | |
Bone/joint infection | 2 (6) | 25 (25) | 0.40 | |
Pulmonary infection | 6 (17) | 35 (14) | 0.65 | |
GU infection | 0 (0) | 22 (9) | 0.05 | |
Incubation Period | 26.8 (67.4) | 12.4 (24.0) | 0.21 | |
Outcome | ||||
Fever days | 2.7 (4.8) | 3.7 (5.0) | 0.11 | |
Time to effective therapy | 1.06 (2.6) days | 1.8 (3.7) days | 0.12 | |
Length of stay after culture | 10.1 (11.3) days | 13.5 (14.1) days | 0.17 |
Risk factor | Hazard Ratio (95% CI) | P value |
---|---|---|
Urine culture positive for S. aureus
| 2.87 (1.411-5.851) | 0.004 |
Bladder catheter present | 1.96 (0.966-3.965) | 0.063 |
Line infection/phlebitis | 0.268 (0.060-1.199) | 0.085 |
Charlson score | 1.183 (1.063-1.316) | 0.018 |
Risk Factora
| Urine culture positive | Urine culture negative | OR (95% CI) | P value |
---|---|---|---|---|
N | 57 | 232 | ||
Demographics | ||||
Age | 49.1 (13.8) | 47.9 (13.8) | 0.59 | |
Male | 40 (70) | 158 (68) | 0.76 | |
Race/Ethnicity | 0.10 | |||
Black | 26 (46) | 141 (61) | ||
Hispanic | 14 (25) | 39 (17) | ||
Other Race | 4 (7) | 21 (9) | ||
White | 13 (22) | 31 (13) | ||
Microbiological factor | ||||
Epidemiological Risk | ||||
Community onset | 26 (46) | 54 (23) | <0.001 | |
Healthcare associated | 18 (32) | 61 (26) | ||
Hospital onset | 13 (23) | 117 (50) | ||
MRSA | 21 (37) | 99(43) | 0.42 | |
Clinical Factors | ||||
Immunosuppressed | 9 (16) | 44 (19) | 0.58 | |
Incubation Period | 15.7 (30.5) | 13.8 (33.4) | 0.68 | |
Charlson Score | 2.05 | 2.15 | 0.801 | |
Hemodialysis | 3 (5) | 24 (10) | 0.24 | |
HIV | 11 (19) | 23 (10) | 2.17 (1.00 - 4.77) | 0.05 |
Endocarditis | 7 (12) | 17 (7) | 0.22 | |
Bladder catheter | 20 (35) | 85 (37) | 0.83 | |
Urological surgery | 6 (11) | 7 (3) | 3.78 (1.22 - 11.73) | 0.03 |
DM | 19 (33) | 64 (28) | 0.39 | |
IVDA | 7 (12) | 39 (17) | 0.40 | |
Prosthetic device | 11 (19) | 55 (24) | 0.48 | |
Alcoholism | 11 (19) | 36 (16) | 0.49 | |
Line infection/phlebitis | 6 (11) | 52 (22) | 0.41 (0.17 - 1.00) | 0.05 |
Skin soft tissue infection | 10 (18) | 47 (20) | 0.64 | |
Bone/joint infection | 7 (12) | 20 (9) | 0.39 | |
Pulmonary infection | 12 (21) | 29 (13) | 1.87 (0.89 - 3.94) | 0.10 |
GU infection | 12 (21) | 10 (4) | 5.92 (2.41 - 14.54) | <0.001 |
Risk factor | OR (95% CI) | P value |
---|---|---|
Urological surgery | 4.47 (1.03-19.30) | 0.045 |
GU infection | 5.70 (1.90-17.12) | 0.002 |